Floatz Rating
B57/100
Confidence
Indicative
Sponsor
IRCCS San Raffaele Roma
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06868953CT.gov Use of the Combination of Sumatriptan and Naproxen in the Acute Treatment of Migraine: Real World Evidence Study | — | Not Yet Recruiting | — | — | — |
NCT07103694CT.gov i-NEED: NEw migrainE Drugs Database | — | Recruiting | — | — | — |
NCT02643719CT.gov Migraine Treatment in ED | — | Withdrawn | — | — | — |
NCT01667679CT.gov Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura | — | Completed | — | — | — |
NCT01381497CT.gov Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sumatriptan Hemisulphate (this asset) | IRCCS San Raffaele Roma | P3 | B · 57 |
| Atogepant | Stanford University | P4 | A |
| Zolmitriptan | Zosano Pharma Corporation | P4 | A |
| Rizatriptan | Antonios Likourezos | P4 | A |
| Naproxen | IRCCS San Raffaele Roma | P4 | A |
| Ubrogepant | H. Lundbeck A/S | P4 | BBB |
| Dfn-11 (Sumatriptan Injection) | IRCCS San Raffaele Roma | P4 | BBB |
| Eptinezumab | Stanford University | P4 | BBB |
| Eletriptan | Boehringer Ingelheim | P4 | BBB |
+42 more in the Migraine Disorder cohort
Other indications for Sumatriptan Hemisulphate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Headache Disorder | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sumatriptan Hemisulphate in Migraine Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sumatriptan-hemisulphate-migraine-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →